Literature DB >> 24453046

Silencing of LASS2/TMSG1 enhances invasion and metastasis capacity of prostate cancer cell.

Xiaoyan Xu1, Beiying Liu, Pengcheng Zou, Yan Zhang, Jiangfeng You, Fei Pei.   

Abstract

Homo sapiens longevity assurance homolog 2 of yeast LAG1 (LASS2), also known as tumor metastasis suppressor gene 1 (TMSG1), was firstly cloned by our laboratory in 1999. However, its antitumor molecular mechanisms are still unclear. LASS2/TMSG-1 could directly interact with the C subunit of Vacuolar H(+) ATPase (V-ATPase), which suggested that LASS2/TMSG1 might inhibit the invasion and metastasis through regulating the function of V-ATPase. In this study, we explored the effect of small hairpin RNA (shRNA) targeting LASS2/TMSG1 on the invasion and metastasis of human prostate carcinoma cell line PC-3M-2B4 with low metastatic potential and its functional interaction with V-ATPase. Silencing of LASS2/TMSG1 gene in PC-3M-2B4 cells increased V-ATPase activity, extracellular hydrogen ion concentration and in turn the activation of secreted MMP-2 and MMP-9, which coincided with enhancing cell proliferation, cell survival, and cell invasion in vitro, as well as acceleration of prostate cancer (PCA) growth and lymph node metastases in vivo. Thus we concluded that silencing of LASS2/TMSG1 enhances invasion and metastasis of PCA cell through increase of V-ATPase activity. These results establish LASS2/TMSG1 as a promising therapeutic target for advanced PCA.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  LASS2/TMSG1; PC-3M-2B4 CELLS; PROSTATE CARCINOMA; VACUOLAR H+ ATPase; shRNA

Mesh:

Substances:

Year:  2014        PMID: 24453046     DOI: 10.1002/jcb.24716

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

1.  miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.

Authors:  Haifeng Wang; Wei Zhang; Yigang Zuo; Mingxia Ding; Changxing Ke; Ruping Yan; Hui Zhan; Jingyu Liu; Jiansong Wang
Journal:  Tumour Biol       Date:  2015-07-07

2.  Silencing of TMSG1 enhances metastasis capacity by targeting V-ATPase in breast cancer.

Authors:  Yuan Zi; Wenjian Zhao; Jun Zhou; Hanjiang He; Ming Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity.

Authors:  Fang Mei; Jiangfeng You; Beiying Liu; Mengxue Zhang; Jiangying Liu; Bo Zhang; Fei Pei
Journal:  Tumour Biol       Date:  2014-12-12

4.  Role of pH Regulatory Proteins and Dysregulation of pH in Prostate Cancer.

Authors:  Larry Fliegel
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

5.  MiR-145 suppresses the motility of prostate cancer cells by targeting cadherin-2.

Authors:  Huixuan Zeng; Yishan Huang; Qiuling Liu; Hongjiao Liu; Tianzhu Long; Cairong Zhu; Xiaoping Wu
Journal:  Mol Cell Biochem       Date:  2021-05-27       Impact factor: 3.396

Review 6.  The Function of V-ATPases in Cancer.

Authors:  Laura Stransky; Kristina Cotter; Michael Forgac
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

7.  Identification of prostate cancer biomarkers in urinary exosomes.

Authors:  Anders Øverbye; Tore Skotland; Christian J Koehler; Bernd Thiede; Therese Seierstad; Viktor Berge; Kirsten Sandvig; Alicia Llorente
Journal:  Oncotarget       Date:  2015-10-06

8.  Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma.

Authors:  Haoyu Ruan; Ting Wang; Chen Yang; Guangzhi Jin; Dishui Gu; Xuan Deng; Cun Wang; Wenxin Qin; Haojie Jin
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

9.  LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity.

Authors:  Haifeng Wang; Yigang Zuo; Mingxia Ding; Changxing Ke; Ruping Yan; Hui Zhan; Jingyu Liu; Wei Wang; Ning Li; Jiansong Wang
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

10.  F-actin reorganization by V-ATPase inhibition in prostate cancer.

Authors:  Yamhilette Licon-Munoz; Vera Michel; Colleen A Fordyce; Karlett J Parra
Journal:  Biol Open       Date:  2017-11-15       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.